Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.

doi:10.18632/oncotarget.1906

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.

Oncotarget - 30 Apr 2014

Okamoto Isamu, Sakai Kazuko, Morita Satoshi, Yoshioka Hiroshige, Kaneda Hiroyasu, Takeda Koji, Hirashima Tomonori, Kogure Yoshihito, Kimura Tatsuo, Takahashi Toshiaki, Atagi Shinji, Seto Takashi, Sawa Toshiyuki, Yamamoto Masashi, Satouchi Miyako, Okuno Motoyasu, Nagase Seisuke, Takayama Koichi, Tomii Keisuke, Maeda Tadashi, Oizumi Satoshi, Fujii Shinji, Akashi Yusaku, Nishino Kazumi, Ebi Noriyuki, Nakagawa Kazuhiko, Nakanishi Yoichi, Nishio Kazuto

Abstract excerpt

Archival formalin-fixed, paraffin-embedded (FFPE) tumor specimens were collected from advanced NSCLC patients enrolled in LETS phase III trial comparing first-line S-1/carboplatin with paclitaxel/carboplatin and subjected to multiplex genotyping for 214 somatic hotspot mutations in 26 genes (LungCarta Panel) and 20 major variants of ALK, RET, and ROS1 fusion genes (LungFusion Panel) with the Sequenom MassARRAY...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Drug Combinations

Share to In Situ Hybridization, Fluorescence

Share to Kaplan-Meier Estimate

Share to Mass Spectrometry

Share to Multiplex Polymerase Chain Reaction

Share to Paclitaxel

Source

Open in PubMed Open full text

Identifiers

PMID: 24810493
DOI: 10.18632/oncotarget.1906
PMCID: PMC4039163

Genes

MET
ALK
EGFR
KRAS
RET
ROS1
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.PMID 24810493Read ↗

Tumor molecular profiling of NSCLC patients using next generation sequencing.Semantic proximity Read ↗

The impact of genomic changes on treatment of lung cancer.Semantic proximity Read ↗

Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patientsSemantic proximity Read ↗

High‐throughput diagnostic profiling of clinically actionable gene fusions in lung cancerSemantic proximity Read ↗

A newly developed capture-based sequencing panel for genomic assay of lung cancer.Semantic proximity Read ↗

A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer.Semantic proximity Read ↗

Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.Semantic proximity Read ↗

Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays.Semantic proximity Read ↗

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencingSemantic proximity Read ↗

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.Semantic proximity Read ↗

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.Semantic proximity Read ↗

Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.